Eli Lilly announced Monday that its experimental gene-editing therapy achieved a 62% reduction in cholesterol levels in participants receiving the highest dose during a Phase 1 clinical trial. The treatment, called VERV-102, targets the PCSK9 gene to provide what researchers hope will be a permanent solution to high cholesterol.
VERV-102 Cholesterol Reduction by Dose Level
LDL cholesterol reduction from baseline, Phase 1 trial results
Source: Eli Lilly Phase 1 Trial Data, 2026 | Georgian Medical Journal News
Single-Dose Therapy Shows Sustained Effects
The Phase 1 trial evaluated VERV-102 as a potential one-time treatment for patients with familial hypercholesterolemia and cardiovascular disease. According to FDA clinical trial protocols, Phase 1 studies primarily assess safety while providing initial efficacy signals.
The gene-editing approach targets the PCSK9 gene in liver cells, aiming to permanently reduce production of a protein that prevents cholesterol removal from the bloodstream. This mechanism represents a significant departure from daily statin therapy, which currently serves as the WHO-recommended first-line treatment for cholesterol management.
For comprehensive coverage of cardiovascular research developments, see our clinical updates section.
Safety Profile Under Continued Evaluation
Eli Lilly reported that VERV-102 demonstrated an acceptable safety profile in the Phase 1 study, though detailed adverse event data have not been publicly disclosed. The company plans to advance the therapy into Phase 2 trials pending regulatory approval from the FDA’s Investigational New Drug program.
Gene-editing therapies face unique regulatory scrutiny due to their permanent modifications to cellular DNA. The National Institutes of Health requires extensive long-term follow-up for participants in gene therapy trials to monitor for delayed effects.
Market Impact and Future Development
The results position Eli Lilly as a competitor in the emerging gene-editing therapeutics market, valued at $8.2 billion globally according to recent market analysis. Verve Therapeutics, Lilly’s partner in developing VERV-102, specializes in cardiovascular gene editing applications.
If approved, VERV-102 would compete with established PCSK9 inhibitors like Repatha and Praluent, which require biweekly or monthly injections. The potential for a single-dose treatment could transform cholesterol management for high-risk patients, particularly those with genetic forms of hypercholesterolemia.
Stay informed about breakthrough therapies through our latest research coverage.
High-dose VERV-102 achieved 62% reduction in LDL cholesterol levels in Phase 1 trial participants, representing the largest reduction seen with a single-dose gene therapy approach.
— Eli Lilly Clinical Trial Data (Phase 1 Study, 2026)
Key takeaways
- VERV-102 gene editor reduced cholesterol by 62% at highest dose in Phase 1 trial
- Single-dose treatment targets PCSK9 gene for potentially permanent cholesterol control
- Phase 2 trials planned pending FDA approval for continued development
- Therapy could offer alternative to daily statins for high-risk cardiovascular patients
Frequently asked questions
How does VERV-102 differ from current cholesterol medications?
Unlike daily statins or injectable PCSK9 inhibitors, VERV-102 uses gene editing to permanently modify liver cells, potentially requiring only a single treatment. The therapy targets the PCSK9 gene directly rather than blocking the protein after it’s produced.
What are the safety concerns with gene-editing therapies?
Gene-editing treatments carry risks of unintended DNA changes and long-term effects that may not appear immediately. Regulatory agencies require extensive safety monitoring and follow-up studies extending several years after treatment.
When might VERV-102 become available to patients?
The therapy must complete Phase 2 and Phase 3 clinical trials before seeking FDA approval. Based on typical development timelines, availability could be 5-7 years away if trials demonstrate continued safety and efficacy.
The successful Phase 1 results mark a significant milestone for cardiovascular gene therapy, though larger studies will be needed to confirm both long-term safety and sustained efficacy. As precision medicine approaches gain regulatory acceptance, VERV-102 represents the potential for transforming chronic disease management from lifelong medication regimens to single-intervention treatments.
Source: STAT+: Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
